Atorvastatin‐Associated Liver Injury: Outcome After Statin Rechallenge
Fundamental & Clinical Pharmacology · 2026-03 · 40 (2)
DOI: 10.1111/fcp.70073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 15.02.2026. Verfasst von Blandine Bertin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Atorvastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Statin‐induced liver injury is frequent and usually not severe. The aim of the present study was to describe the safety of statin rechallenge after atorvastatin‐induced liver injury because it is poorly documented.
Methods
Cases of liver injury involving atorvastatin were selected from the French pharmacovigilance database. Inclusion criteria were a documented atorvastatin or any other statin reintroduction and an available follow‐up of at least 2 weeks to define negative rechallenge.
Results
Twenty‐six cases of atorvastatin liver injury with further statin reintroduction met our criteria. Median time to onset (TTO) of the first episode was 27 days (IQR: 4–43), with a cholestatic pattern in 11 (42.3%) cases, cytolytic in nine (34.6%), and mixed in six (23.1%); severity ranked Grade 2 in 11 (42.3%). Atorvastatin rechallenge was positive in 12 of 16 patients with the same dose (11 of 13) or a reduced dose (1 of 3), and the TTO was shorter (median 11 days). Rechallenge with an alternative statin was performed in 10 patients, of whom two experienced recurrence with rosuvastatin and simvastatin. No recurrence was observed after rechallenge of rosuvastatin in five, pravastatin in two, and simvastatin in one.
Conclusion
Our study evidenced frequent recurrence of drug‐induced liver injury after atorvastatin rechallenge, whereas subsequent administration of a hydrophilic statin was well tolerated. By combining our data and published cases, we suggest that rosuvastatin or pravastatin carries the lowest risk of recurrence. Study limitations include a focus solely on atorvastatin, a retrospective design, and potential underreporting to the pharmacovigilance system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.
- Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France.
- HP2 Laboratory, Inserm U1300, Université Grenoble Alpes, Grenoble, France.
- Franche-Comté Regional Pharmacovigilance and Drug Information Center, Besançon University Hospital, Besançon, France.
- Department of Digestive Diseases, Hospices Civils de Lyon, Edouard Herriot Hospital, Claude Bernard Lyon 1 University, Lyon, France.
ORCID-Profile: Blandine Bertin, Jean-Luc Cracowski, Anais Gaiffe, Jérôme Dumortier
Zitieren
APA
Bertin, B., Lacotte, V., Cracowski, J. L., Gaiffe, A., Dumortier, J., & Vial, T. (2026). Atorvastatin‐Associated Liver Injury: Outcome After Statin Rechallenge. Fundamental & Clinical Pharmacology, 40(2). https://doi.org/10.1111/fcp.70073
Vancouver
Bertin B, Lacotte V, Cracowski JL, Gaiffe A, Dumortier J, Vial T. Atorvastatin‐Associated Liver Injury: Outcome After Statin Rechallenge. Fundamental & Clinical Pharmacology. 2026;40(2). doi:10.1111/fcp.70073
BibTeX
@article{Bertin2026,
author = {Bertin, Blandine and Lacotte, Valentine and Cracowski, Jean-Luc and Gaiffe, Anais and Dumortier, Jérôme and Vial, Thierry},
title = {Atorvastatin‐Associated Liver Injury: Outcome After Statin Rechallenge},
journal = {Fundamental & Clinical Pharmacology},
year = {2026},
volume = {40},
number = {2},
doi = {10.1111/fcp.70073}
}
EUVIMED